HUMA Humacyte, Inc.
8-K Current Report
Filed: March 19, 2026
Health Care
Biological Products, (No Diagnostic Substances)Humacyte, Inc. (HUMA) 8-K current report filed with SEC EDGAR on March 19, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Preliminary financial results for year ended December 31, 2025 disclosed under "Operational Updates"
- • No specific financial figures included in Item 2.02; refer to exhibit or press release for details
Item 8.01 · Other Events
- • Suspension of $60M ATM equity offering prospectus limits near-term capital raise options using sales agreement with TD Cowen
- • Preliminary 2025 financials: $50.9M cash, $2.0M revenue incl. $1.4M product sales, 61 Symvess units sold, pending final audit
Other Humacyte, Inc. 8-K Filings
Get deeper insights on Humacyte, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.